Evidence map›Paper›PMID 40145524›Full record

ReviewRevista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia2025

Towards a holistic approach to pulmonary infections. Insights from the Sixth Annual Meeting of Spanish Experts 2024.

Cristobal M Rodriguez-Leal, Carlos González-Corralejo, Francisco Javier Candel, Miguel Salavert, collaborative authors, members of the Study Group of Infections in Critically Ill Patients - Spanish Society of Clinical Microbiology and Infectious Diseases (GEIPC-SEIMC), and medical societies represented in 6th edition of Pneumonia Day (Addenda)

Abstract readReview
In one paragraph

Review in Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Challenges and opportunities in the management of severe pneumonia. Key concepts from the Seventh Annual Meeting of Spanish Experts 2025.Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2026
    Review
  2. Review
  3. Frontiers in microbiology · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Cristobal M Rodriguez-LealEmergency Medicine Department, Hospital Universitario del Henares, Coslada, Madrid, Spain.ORCID 0000-0001-7144-2015
Carlos González-CorralejoClinical Microbiology Department, Hospital Universitario Clínico San Carlos, IdISSC & IML Health Research Institutes, Madrid, Spain.ORCID 0000-0003-0343-7251
Francisco Javier CandelEmergency Research Group, Spanish Society of Emergency Medicine (INFURGSEMES-SEMES), Spain.ORCID 0000-0002-9840-6556
Miguel SalavertSpanish Society of Clinical Microbiology and Infectious Diseases (SEIMC), Spain.ORCID 0000-0002-8571-2124
collaborative authors, members of the Study Group of Infections in Critically Ill Patients - Spanish Society of Clinical Microbiology and Infectious Diseases (GEIPC-SEIMC), and medical societies represented in 6th edition of Pneumonia Day (Addenda)

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pneumonia is the leading cause of death from infection in the developed world. In recent years, researchers and healthcare professionals have worked extensively to reduce this burden. Prevention is better than cure, and significant advances have been made in areas such as vaccination and the prevention of nosocomial pneumonia in intensive care units. Comprehensive surveillance programmes and new diagnostic methods have been developed to assess trends in this disease and to identify the infectious agents involved. Clinical presentation can be challenging in elderly patients or those with certain comorbidities, prompting new studies in these populations to address these issues. Correct and early management of severe community-acquired pneumonia represents a major opportunity to reduce its associated mortality. Although fungal pathogens are an uncommon cause of lung infection, they are associated with high morbidity and mortality, highlighting the need for new approaches. Finally, new drugs are available for the treatment of pneumonia, and a thorough understanding of them is key to ensuring their correct use, particularly to combat multi-resistance. To provide an update on these points, a multidisciplinary team of Spanish experts convened at the Sixth Annual Meeting of Pneumonia Day, under the scientific sponsorship of GEIPC-SEIMC. This paper reflects the information shared at this meeting, offering the latest insights on these topics and supporting a holistic approach to pneumonia management.

Indexed as

PneumoniaCommunity-Acquired InfectionsCross InfectionHumansSpainAetiologyCommunity acquired pneumoniaDiagnosis stewardshipEpidemiologyManagementNosocomial pneumonia Healthcare-associated pneumoniaPreventionTherapeutic failure

Identifiers

PMID40145524
PMCPMC12095940

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.